GTH News and Press, Genetron Holdings Limited From 11/29/20

Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed for China approval of at least one of its two COVID-19 inactivated vaccines based on in...

Genetron ([[GTH]] +1.5%) says HCCscreen selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative in China.The goal of the Project is t...

HCCscreen TM was selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative Establishes joint venture with Wuxi municipal ...

The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, according to Sizhen Wang, co-founder and chief executive officer of Genetron Holdings Limited (“Genetron Health&#x...

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, ...

The following slide deck was published by Genetron Holdings Limited in conjunction with this event. For further details see: Genetron (GTH) Investor Presentation - Slideshow

BEIJING, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products ...

Genetron Holdings went public in June 2020 and just reported its Q3 2020 results. The firm provides a range of cancer diagnostic and monitoring services in China. GTH is producing a positive topline revenue and gross profit growth trajectory as it nears earnings breakeven, so I'm ...

Genetron Holdings (GTH): Q3 Non-GAAP EPS of -$0.01; GAAP EPS of -$0.02.Revenue of $16.49M (+37.6% Y/Y).Press Release For further details see: Genetron Holdings reports Q3 results

BEIJING, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products a...